RT @ericdeinmd: Ab#0348 #ACR22: Meta-analysis of Belimumab for CLE w or w/o SLE 13 studies included: 70% with low risk o

Eric Dein @ericdeinmd Nov 12, 2022

Ab#0348 #ACR22: Meta-analysis of Belimumab for CLE w or w/o SLE
13 studies included: 70% with low risk of bias
BEL improved clinical response at W52 vs non-users OR 1.44
Decrease risk of severe cutaneous flare OR 0.51
Most studies against placebo group
@RheumNow